China CanSinoBIO’s vaccine 57.5 per cent effective against COVID in phase-III trial: Study Reuters Dec 24, 2021 The single-shot Ad5-nCoV vaccine, which CanSinoBIO co-developed with the Chinese military-backed Beijing Institute of…
